Although neuromedin U was identified more than 30 years ago [16], there are still many questions regarding peptide processing, generation, secretion, activity and target cells; additionally, expression of the NMU receptors and responsiveness of cancer and other cells in the tumour microenvironment are not fully understood. This evidence concerns the gene NMU and cancer.